Take a trial of UK to unlock this pageFind out more

Smith & Nephew

SN. 1237p 13.0  1.1%
30/08/16 2.00k

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2010 2011 2012 2013 2014 2015 TTM 2016E 2017E CAGR / Avg
Revenue $m
Operating Profit $m
Net Profit $m
EPS Reported $
EPS Normalised $
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps $
Capex ps $
Free Cashflow ps $
Last ex-div: 6th Oct, paid: 25th Oct more... Dividends
Dividend ps $
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc $m
Working Capital $m
Net Fixed Assets $m
Net Debt $m
Book Value $m
Average Shares m
Book Value ps $ +7.4%

FINANCIAL BRIEF: For the six months ended 02 July 2016, Smith & Nephew plc revenues increased 2% to $2.33B. Net income decreased 18% to $241M. Revenues reflect Established Markets segment increase of 20% to $850M, United States segment increase of 8% to $1.15B. Net income was offset by Interest receivable decrease of 71% to $2M (income), Research and development expenses increase of 3% to $113M (expense). Dividend per share remained flat at $0.12. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
C+
C+
Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 2nd Jul '16) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2016
31st Dec 2017

Price Target: $17.5
(+8.81% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: +8.9% ($) (¢) (¢) ($) (¢) (¢)
Consensus Estimate
1m Change
3m Change
13 brokers Broker Consensus Trend
Broker Recommendations for Smith & Nephew
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 9 4 4

Named Brokers and Analysts
Jefferies Chris Cooper , Credit Suisse Christoph Gretler , BERNSTEIN , Investec Bank (UK) Plc Cora McCallum , Canaccord Genuity William Plovanic , Brean Capital, LLC Jason Wittes , Northland Securities , Panmure Gordon Savvas Neophytou , Numis Securities Sally Taylor , Edison Investment Research Linda Pomeroy , Societe Generale Justin Smith , Berenberg Tom Jones , Morningstar, Inc. Debbie Wang , Day by Day Valérie GASTALDY , Cantor Fitzgerald Europe Brian White ,

Profile Summary

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. The Company offers various product franchises, which include Knee implants, Hip implants, Sports Medicine Joint Repair, Arthroscopy Enabling Technologies, Trauma and Extremities, Other Surgical Businesses, Advanced Wound Care, Advanced Wound Devices and Advanced Wound Bioactives. Its knee systems include LEGION/GENESIS II Total Knee System and JOURNEY II Family of Active Knees. Its hip systems include the ANTHOLOGY Hip System, SYNERGY Hip System, the SMF Femoral Hip System, POLARSTEM Femoral Hip System, the R3 Acetabular System and the POLARCUP Dual Mobility Hip System. Its Sports Medicine Joint Repair products include the FAST-FIX family of meniscal repair systems, the ENDOBUTTON family for knee ligament reconstruction, HEALICOIL PK, FOOTPRINT PK and TWINFIX Suture anchors for repairs of the hip and rotator cuff.

Directors: Olivier Bohuon (CEO) 57, Julie Brown (CFO) 53, Rodrigo Bianchi (CEX) 55, Michael Frazzette (CEX) 53, R. Gordon Howe (CEX) 52, Diogo Moreira-Rato (CEX) 53, Glenn Warner (CEX) 52, John Campo (OTH) 60, Helen Maye (OTH) 55, Cyrille Petit (OTH) 44, Roberto Quarta (NEC) 66, Robin Freestone (NED) 56, Vinita Bali (NID) 60, Ian Barlow (NID) 64, Virginia Bottomley (NID) 67,

No. of Employees: 14,686 No. of Shareholders: 17,487


Last Annual December 31st, 2015
Last Interim July 2nd, 2016
Incorporated February 17, 1937
Public Since August 13, 1951
Shares in Issue 892,582,253
Free Float 886.0m (99.3%)

SN. Share Price Performance SN.Quote
1237p
13.0  1.1%
Traded 4:35pm · Minimum 15 min delayed · NMS: 2.00k

Latest SN. News Announcements (delayed)

Upcoming SN. Events
Thursday 6th October, 2016
Dividend For SN.L
Thursday 3rd November, 2016
Q3 2016 Smith & Nephew PLC Trading Statement Release
Wednesday 1st February, 2017 (estimate)
Q4 2016 Smith & Nephew PLC Earnings Release

Recent ↓
Thursday 28th July, 2016
Q2 2016 Smith & Nephew PLC Earnings Call
Thursday 28th July, 2016
Q2 2016 Smith & Nephew PLC Earnings Release
Thursday 28th July, 2016
Q2 2016 Smith & Nephew PLC Trading Statement Release
Thursday 9th June, 2016
Smith & Nephew PLC at Deutsche Bank ADR Virtual Investor Conference
Thursday 5th May, 2016
Q1 2016 Smith & Nephew PLC Trading Statement Call
Thursday 5th May, 2016
Q1 2016 Smith & Nephew PLC Trading Statement Release
Thursday 21st April, 2016
Dividend For SN.L
Wednesday 20th April, 2016
Dividend For SNN
Thursday 14th April, 2016
Smith & Nephew PLC Annual Shareholders Meeting
Tuesday 1st March, 2016
Smith & Nephew PLC at Canaccord Genuity Musculoskeletal Conference
Thursday 4th February, 2016
Q4 2015 Smith & Nephew PLC Earnings Call
Thursday 4th February, 2016
Q4 2015 Smith & Nephew PLC Earnings Release
Wednesday 18th November, 2015
Smith & Nephew PLC at Jefferies Autumn Global Healthcare Conference
Tuesday 10th November, 2015
Smith & Nephew PLC Capital Markets Event
Thursday 29th October, 2015
Q3 2015 Smith & Nephew PLC Trading Statement Call
Thursday 29th October, 2015
Q3 2015 Smith & Nephew PLC Trading Statement Release
Wednesday 7th October, 2015
Dividend For SNN
Thursday 30th July, 2015
Q2 2015 Smith & Nephew PLC Earnings Call
Thursday 30th July, 2015
Q2 2015 Smith & Nephew PLC Earnings Release
Thursday 30th April, 2015
Q1 2015 Smith & Nephew PLC Trading Statement Call


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2016.


Should you buy SN.

Access SN. Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis
Foliobuilder